Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Friday, May 30, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward hematologists/oncologists, medical oncologists, and other HCPs involved in the treatment and management of MM.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze efficacy and safety data from pivotal trials evaluating new and emerging therapies for relapsed/refractory multiple myeloma (R/R MM)
- Balance disease- and patient-specific factors to formulate individualized treatment plans for patients with early relapsed MM
- Incorporate evidence-based strategies to select and sequence T-cell therapies for heavily pretreated patients with R/R MM
- Implement proactive measures to mitigate treatment-related toxicities in patients with R/R MM
C. Ola Landgren, MD, PhD
Professor of Medicine, University of Miami
Chief, Division of Myeloma & Myeloma Institute
Paul J. DiMare Endowed Chair in Immunotherapy
Chief, Riney Family Multiple Myeloma Research Program
Co-Director, Translational and Clinical Oncology Program
Sylvester Comprehensive Cancer Center
Professor of Medicine
University of Miami Leonard M. Miller School of Medicine
Miami, FL
Disclosures: Advisory board: AbbVie, GSK, Janssen, Regeneron, Sanofi; Research Support: Amgen, Janssen.
Mohamad Mohty, MD, PhD
Professor of Hematology
Head of the Hematology and Cellular Therapy Department Saint-Antoine
Hospital
Sorbonne University
Paris, France
Disclosures: Consulting Fees: Amgen, Adaptive Biotechnologies, Astellas, Bristol-Myers Squibb, GSK, Janssen, Novartis, Pfizer, Sanofi, Stemline, Takeda; Grants and contracts from an entity: Janssen, Novartis, Sanofi; Manuscript writing or educational events: Amgen, Adaptive Biotechnologies, Astellas, Bristol-Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Payment or honoraria for lectures: Amgen, Adaptive Biotechnologies, Astellas, Bristol-Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Presentations: Amgen, Adaptive Biotechnologies, Astellas, Bristol-Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda; Speakers’ Bureau: Adaptive Biotechnologies, Amgen, Astellas, Bristol-Myers Squibb, GSK, Janssen, MAAT, Novartis, Pfizer, Sanofi, Stemline, Takeda.
Surbhi Sidana, MD
Associate Professor of Medicine
Director, Myeloma Disease Focused Group
Division of BMT & Cell Therapy
Stanford University
Stanford, CA
Disclosures: Consulting or Advisory role: AbbVie, Arcellx, Bioline, Bristol-Myers Squibb, Genentech, Janssen, Kite, Legend, Pfizer, Regeneron, Roche, Sanofi, Takeda; Research funding: Allogene Therapeutics, Bristol-Myers Squibb, Janssen, Magenta Therapeutics, Novartis.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.